Research Article

Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer

Table 4

Univariate and multivariate analysis of clinicopathological parameters regarding overall survival (OS), progression-free survival (PFS), local control rate (LCR), and distant metastasis-free survival (DMFS); for 135/158 patients available; for 116/158 patients available.

CategoriesUnivariate analysis
OSPFSLCRDMFS
HRCI 95%p valueHRCI 95%p valueHRCI 95%p valueHRCI 95%p value

p16 status; neg/po1.650.83–3.280.1532.3510.996–5.5480.0512.0880.811–5.3710.1276.0440.806–45.3050.08
Smoker/non1.8461.054–3.2330.0321.5030.777–2.9060.2261.3870.664–2.8950.3842.8401.029–7.8350.044
Sex male/female1.0080.577–1.7630.9771.2710.691–2.3390.441.0040.496–2.0350.991.3640.532–3.4960.518
T3-4/T1-21.1250.453–2.7920.81.1920.430–3.3030.7361.0680.331–3.4530.9122.4740.730–8.3690.146
N3/N2/N0-12.0041.098–3.6590.0242.0021.008–3.9740.0471.4980.732–3.0620.2683.1041.016–9.4830.047
G3/G2/G10.750.480–1.1720.2060,8690.511–1.4780.6040,8040.445–1.4540.4711.5180.680–3.3870.309
ECOG2-3/ECOG0-12.3031258–4.1290.0052.0921.060–4.1290.0332.5891.246–5.3800.0111.5500.521–4.6150.431
Age < 65/≥650.8950.558–1.4360.6461.3100.737–2.3270.3571.1310.606–2.1100.6990.6510.255–1.6660.371
Age < 70/≥700.9120.524–1.5890.7461.0570.545–2.0490.8710.8920.441–1.8060.7510.590.174–1.9940.396
Age < 75/≥750.870.417–1.8140.711.0690.426–2.6840.8870.8330.328–2.1150.7010.9180.214–3.9320.909

CategoriesMultivariate analysis
OSPFSLCRDMFS
HRCI 95%p valueHRCI 95%p valueHRCI 95%p valueHRCI 95%p value

Smoker/nonsmoke2.3211.287–4.1830.0053.2221.130–9.1890.029
N3/N2/N0-12.3560.947–5.8630.0661.8190.859–3.8520.1186.8901.479–32.1090.014
ECOG2-3/ECOG0-12.5731.344–4.9280.0041.9901.007–3.9330.048